Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.47 |
| ▸ | UBE2M | P61081 | 3/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774218 | 0.96 | OPRM1 (0.50) | OPRM1TMEM97UBE2MDCUN1D1CHRM2 | |
| Trifluoroacetic Acid SCHEMBL5774584 | 0.90 | MEN1 (0.44) | OPRM1TMEM97CHRM2CHRM3DRD2 | |
| SCHEMBL5771833 | 0.86 | DRD2 (0.42) | OPRM1TMEM97UBE2MDCUN1D1DRD2 | |
| Trifluoroacetic Acid SCHEMBL5771830 | 0.82 | DRD2 (0.54) | TMEM97DRD2DRD4 | |
| SCHEMBL5773476 | 0.80 | DRD2 (0.46) | OPRM1UBE2MDCUN1D1DRD2DRD4 | |
| Trifluoroacetic Acid SCHEMBL5776822 | 0.79 | DPP8 (0.50) | — | |
| Trifluoroacetic Acid SCHEMBL5774450 | 0.77 | HTT (0.40) | LMNA | |
| Trifluoroacetic Acid SCHEMBL5773475 | 0.77 | DRD4 (0.58) | DRD2DRD4 | |
| Trifluoroacetic Acid SCHEMBL5776131 | 0.76 | LMNA (0.42) | LMNA | |
| SCHEMBL5771825 | 0.75 | KCNH2 (0.47) | OPRM1UBE2MDCUN1D1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | OPRM1 463/4885TMEM97 593/4885UBE2M 4238/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | OPRM1 1339/4885TMEM97 805/4885UBE2M 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.